Multi-omics analyses reveal ClpP activators disrupt essential mitochondrial pathways in triple-negative breast cancer

ClpP activators ONC201 and related small molecules (TR compounds, Madera Therapeutics), have demonstrated significant anti-cancer potential in vitro and in vivo studies, including clinical trials for refractory solid tumors. Though progress has been made in identifying specific phenotypic outcomes f...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Emily M. J. Fennell, Lucas J. Aponte-Collazo, Wimal Pathmasiri, Blake R. Rushing, Natalie K. Barker, Megan C. Partridge, Yuan-Yuan Li, Cody A. White, Yoshimi E. Greer, Laura E. Herring, Stanley Lipkowitz, Susan C. J. Sumner, Edwin J. Iwanowicz, Lee M. Graves
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Frontiers Media S.A. 2023-03-01
סדרה:	Frontiers in Pharmacology
נושאים:	ClpP activators CLPP mitochondria multi-omics breast cancer
גישה מקוונת:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1136317/full
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!